New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...

Related Keywords

Canada ,Washington ,United States ,Japan ,University Of Washington ,Spring House ,British Columbia ,Horsham ,Saskatchewan ,Seattle ,Donvitot Creakyjoints ,Terence Rooney ,Philip Mease ,Bridget Kimmel ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Swedish Medical Center Providence ,National Psoriasis Foundation ,None Of The Janssen Pharmaceutical Companies ,Form Health Survey Physical Component Summary ,European Congress ,Joseph Health ,Drug Administration ,Health Assessment Questionnaire ,Guselkumab Provides Sustained Improvements In Health ,Exchange Commission ,Companies Of Johnson ,Group For Research ,Johnson ,Swedish Medical ,Efficacy Across Joint ,Psoriatic Arthritis ,Disease Activity Index ,Radiographic Progression ,Work Productivity ,Short Form ,Vitality Scale ,Functional Assessment ,Chronic Illness Therapy ,Vice President ,Maternal Fetal Disease Area ,Janssen Research ,Disease Activity ,Psoriasis Area Severity Index ,Global Assessment ,Psoriatic Arthritis Disease Activity Score ,Disability Index ,Euroqol Visual Analog Scale ,Item Short Form Health Survey ,Physical Component Summary ,Mental Component Summary ,Prescribing Information ,Medication Guidefor ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Baseline Patient ,Provides Sustained Improvements ,Health Related Quality ,Patients With Active Psoriatic Arthritis Through ,Associated With Fatigue ,Its Improvement ,Principal Component Analysis ,Patients With Active Psoriatic Arthritis ,Guselkumab Phase ,Spain Response ,Psoriatic Arthritis Receiving Treatment ,Daily Activity ,Accessed May ,Provides Continued Improvement ,Key Domains ,Psoriatic Arthritis Through ,Minimal Disease Activity Achievement ,Patients With Psoriatic Arthritis Receiving ,Data From The Phase ,Maintains Resolution ,Results Through ,Axial Related Endpoints ,Patients With Active Psa ,Placebo Controlled Study Through ,Radiographic Progression With ,Selective Inhibitor ,Placebo Controlled Study ,Active Psoriatic ,Arthritis Res Ther ,Clinical Response Predict Low Rates ,Active Psoriatic Arthritis ,Pooled Results From ,Clinical Trials Through ,Safety Analyses ,Long Term Results ,Randomized Clinical Trials ,Patients With Psoriatic Disease Utilizing ,Results Through Week ,Patients With Psoriasis ,Oncol Clin North ,Warm Autoimmune Hemolytic Anemia ,Known Clinically Profiled ,Painful Arthritis Symptom You Should Know ,Sausage Finger Swelling You Should Know ,Psoriatic Arthritis According ,Different Definitions ,Comparing Minimal Disease Activity ,Arthritis Care Res ,Study Evaluating ,Guselkumab Administered Subcutaneously ,Tumor Necrosis Factor ,Alpha Agent ,Participants With Active Psoriatic ,Participants With Active Psoriatic Arthritis ,Inadequate Response ,Anti Tumor Necrosis Factor Alpha ,Rambam Maimonides Med ,About Psoriatic ,Rheumatic Diseases ,Immune Based Therapies ,Janssen Pharmaceutical Companies Of Johnson Amp ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,